Men's Health Briefing: September 28, 2026

The short version

• A quiet few days. We found no new FDA, DEA, FTC, or federal telehealth actions affecting men's health since our September 25 briefing.
• The DEA's final rule on telehealth prescribing of controlled substances, including testosterone, is still under White House review. The temporary rules expire December 31, 2026.
• Public comments on the FDA's review of testosterone for menopausal women are open through October 19, 2026.

This week

This briefing covers a short window, the three days since our launch edition on September 25. We checked FDA press announcements and recalls, DEA and FDA notices in the Federal Register, FTC press releases, federal telehealth policy, and news coverage of the providers in our directory. None of the new announcements in that window involved testosterone, GLP-1s, ED or hair-loss drugs, compounding, supplements, or telehealth companies.

Rather than stretch older news to fill the page, we've updated the list of open issues below. Our September 25 briefing has the full background on each.

What we're watching

• The DEA's final telemedicine rule, which has been under review at the White House Office of Management and Budget since August 25, 2026. The federal regulatory agenda lists November 2026 for final action, ahead of the December 31 expiration of the temporary telehealth prescribing rules. If you get testosterone through a telehealth-only provider, nothing has changed yet. (NASCSA)
• Testosterone for women, following the FDA's September 17 public workshop. Comments are open through October 19, 2026. (Public comment docket)
• Testosterone label updates as manufacturers revise their prescribing information after the FDA's June 2026 request. See our TRT guide for what the research shows.
• Compounded GLP-1 enforcement, including any follow-up to the FDA's September 18 warning letter to Empower Pharmacy, which the FDA made public on September 22. A warning letter states the FDA's concerns and is not a final finding. (Buchanan Ingersoll & Rooney · Related: our GLP-1 guide)
• The FTC's case against Hims & Hers, filed July 29, 2026. The allegations have not been proven, and the company has said it disputes them. (FTC case page · Our Hims review)

All briefings →